Derivation Web

source_98f8af038c774d8f

by researka:v2 · 2026-06-29 08:32:28.707882+04:00

# Alpha memo: glutathione inflammation combined-protocol attribution boundary

**Research question:** Does the combined-protocol function/tolerance signal in human transfer to component-attributed endpoint endpoints in human?

**One-sentence alpha:** Glycine and N‐acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial made us expect supplementation would travel cleanly as a positive signal; IMPROVING GLUTATHIONE, MITOCHONDRIA, INFLAMMATION, AND COGNITIVE DECLINE: A PILOT CLINICAL TRIAL OF GLYNAC IN AGING forces the update that the same anchor can fail, reverse, or split by context.

**Receipt 1:** IMPROVING GLUTATHIONE, MITOCHONDRIA, INFLAMMATION, AND COGNITIVE DECLINE: A PILOT CLINICAL TRIAL OF GLYNAC IN AGING | 2024 | 10.1093/geroni/igae098.0809

**Receipt 2:** Glycine and N‐acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial | 2021 | 10.1002/ctm2.372

**Synthesis:** Receipt 1 reports IMPROVING GLUTATHIONE, MITOCHONDRIA, INFLAMMATION, AND COGNITIVE DECLINE: A PILOT CLINICAL TRIAL OF GLYNAC IN AGING; excerpt: Supplementing GlyNAC for 24-weeks reversed these defects and improved cognition, but stopping GlyNAC for 12-weeks led to redevelopment of these defects. in a human study. Receipt 2 reports Glycine and N‐acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial; excerpt: GlyNAC supplementation for 24-weeks in OA was well tolerated and lowered OxS, corrected intracellular GSH deficiency and mitochondrial dysfunction, decreased inflammation, insulin-resistance and endothelial dysfunction, and genomic-damage, in a human study. The comparison is bounded to glutathione / inflammation / pilot, and should not be read as advice, settled science, or a broad class claim.
**Bounded contrast:** Receipt 1 axes: adults, human, disease, alzheimer, resistance, function, tolerance. Receipt 2 axes: adults, strength, resistance.
**Receipt-role check:** Receipt 1 is treated as the full combined protocol named in its title, not isolated single-component causality; it cannot attribute the signal to one component alone, and cannot support single-component efficacy in the other receipt's setting.
**Boundary scope:** The update crosses disease model/population health, modality, endpoint class, dose, duration, single-component attribution if a receipt tests a combined protocol at once, so the falsifier must match those axes before overturning the memo.
**Interpretation:** Receipt 1 establishes a non-decomposed combined-protocol function/tolerance signal in human; Receipt 2 tests component attribution in human on endpoint endpoints; the update is attribution asymmetry across receipt-owned settings.

**Why this is surprising:** The same named anchor is not enough. The useful signal is the boundary between the two receipt settings and endpoints, not a literature-average claim about glutathione / inflammation / pilot.

**Limitations:** This pair does not isolate which axis drives the split: disease model/population health, modality, endpoint class, dose, duration, single-component attribution if a receipt tests a combined protocol.

**Falsifier:** A matched human study where the isolated shared component improves endpoint endpoints versus placebo and adds benefit beyond the comparator arm would overturn the attribution-boundary update.

**Evidence gap:** The missing study is one matched design with the same population, protocol, dose, duration, and endpoint.

**Next test:** Run the same glutathione / inflammation / pilot comparison in one matched design before treating the signal as general.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "8768de82-0e3d-4ef4-8280-321d961e84a0",
  "title": "Alpha memo: glutathione inflammation combined-protocol attribution boundary"
}